肿瘤免疫检查点抑制剂相关的肝毒性  

Hepatotoxicity associated with tumor immune checkpoint inhibitors

作　　者：雷晓红 唐颖悦 李静[1] 茅益民 Lei Xiaohong;Tang Yingyue;Li Jing;Mao Yimin(Division of Gastroenterology and Hepatology,Key Laboratory of Gastroenterology and Hepatology,Ministry of Health,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai Institute of Digestive Disease,Shanghai 200001,China)

机构地区：[1]上海交通大学医学院附属仁济医院消化内科,上海市消化疾病研究所,上海市脂肪性肝病诊治研究中心,200001

出　　处：《中华肝脏病杂志》2020年第2期175-178,共4页Chinese Journal of Hepatology

基　　金：“十三五”科技重大专项(2017ZX09304016);国家自然科学基金课题(81670524);上海交通大学医学院多中心临床研究项目(DLY201607);上海申康医院发展中心临床创新三年行动计划项目(16CR2009A)。

摘　　要：肿瘤免疫检查点抑制剂治疗为肿瘤患者带来生存获益的同时,也面临了许多挑战,例如免疫介导的肝毒性的发生。深入了解免疫检查点抑制剂治疗肿瘤过程中导致肝损伤的发生情况、可能机制、危险因素等,有助于更好地临床管理。Although tumor immune checkpoint inhibitors therapy brings survival benefits to cancer patients,it also faces many challenges,such as the occurrence of immune-mediated hepatotoxicity.Therefore,an in-depth understanding of the conditions,possible mechanisms,and risk factors that cause liver injury during the treatment of tumor immune checkpoint inhibitors will facilitate better clinical management.

关 键 词：肿瘤 自身免疫性 免疫检查点抑制剂 肝毒性 

分 类 号：R730[医药卫生—肿瘤]